ATTRALUS
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.
ATTRALUS
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
2019-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.attralus.com
Total Employee:
11+
Status:
Active
Total Funding:
141 M USD
Technology used in webpage:
Person Schema
Similar Organizations
Clade Therapeutics
Clade Therapeutics discovers and delivers next-generation cell medicines to improve the lives of patients.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Generate Biomedicines
Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.
Current Advisors List
Current Employees Featured
Founder
Investors List
Sarissa Capital Management
Sarissa Capital Management investment in Series B - Attralus
venBio Partners
venBio Partners investment in Series B - Attralus
Logos Capital
Logos Capital investment in Series B - Attralus
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Attralus
Surveyor Capital
Surveyor Capital investment in Series B - Attralus
Redmile Group
Redmile Group investment in Series B - Attralus
Vivo Capital
Vivo Capital investment in Series B - Attralus
Samsara BioCapital
Samsara BioCapital investment in Series B - Attralus
venBio Partners
venBio Partners investment in Series A - Attralus
Key Employee Changes
| Date | New article |
|---|---|
| 2021-05-10 | Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives |
Official Site Inspections
http://www.attralus.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
